Edwards Lifesciences announced on October 30, 2024, that its EVOQUE system demonstrated superiority compared to medical therapy alone for the one-year primary endpoint of the TRISCEND II trial. This randomized controlled pivotal trial evaluated the EVOQUE transcatheter tricuspid valve replacement (TTVR) system against optimal medical therapy (OMT) alone.
The data, presented during the late-breaking clinical trial sessions at TCT, showed that the EVOQUE system provided significant clinical and quality-of-life benefits for patients with severe tricuspid regurgitation. This outcome reinforces the potential of EVOQUE as a leading treatment option in the rapidly expanding Transcatheter Mitral and Tricuspid Therapies (TMTT) segment.
The positive results from the TRISCEND II trial are expected to support broader adoption and market penetration of the EVOQUE system. This further solidifies Edwards' position as a leader in developing comprehensive treatment options for complex structural heart diseases.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.